Nasdaq
$8.97▼ 0.44%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $441.8MShares out 49.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 3d agoPre-market26.10.22 21:144Ownership#●●●
AgomAb Therapeutics NV
Insider David R. Epstein reported a change in beneficial ownership of AgomAb Therapeutics NV securities on October 21, 2026. This filing is a Form 4 statement submitted to the SEC regarding the insider's equity holdings.…more
$8.97-0.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 06:186-KKey event
AgomAb Therapeutics NV
AgomAb Therapeutics has initiated dosing for the first patient in its global Phase 2b NOV-ERA study evaluating ontunisertib for the treatment of fibrostenosing Crohn's disease. The study aims to enroll approximately 320 patients to assess safety and efficacy, triggering a 7 million euro milestone payment to former shareholders of Origo Biopharma.…more
$8.97-0.44%vs prev closeView filingShare - 10.9Pre-market26.10.09 21:014Ownership
AgomAb Therapeutics NV
Insider David R. Epstein filed a Form 4 statement of changes in beneficial ownership for AgomAb Therapeutics NV on October 8, 2026. This filing serves to officially report the change in the insider's equity holdings.…more
$8.97-0.44%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13After-hours26.10.14 05:06#●●●#●●●
Agomab Doses First Patient in Phase 2b Trial for Crohn's Disease Drug
Agomab Therapeutics has initiated dosing for the first patient in its global Phase 2b study of ontunisertib for fibrostenosing Crohn's disease. The trial aims to evaluate the safety and efficacy of the drug in approximately 320 patients, marking a key milestone in its clinical development.…more
$8.97-0.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8After-hours26.10.09 05:05
●●●●●●●● ●●●●● ●●●●●●
Agomab will present long-term data from the Phase 2a STENOVA study of ontunisertib for fibrostenosing Crohn’s disease at UEG Week 2026. These results support the company's plans to initiate a global Phase 2b trial in the coming months.…more
$8.97-0.44%vs prev close - 10.1Regular26.10.02 03:31
●●●●●●●● ●●●●● ●●●●●●
Agomab Therapeutics confirmed sustained disease control and safety for its Crohn's disease candidate in a Phase 2a extension study. Despite the positive clinical data, the company's stock price dropped significantly by over 17%.…more
$8.97-0.44%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report